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Objective: The pathophysiology of hypertriglyceridemia is complex hampering effective therapeutic
strategies. Increased central parasympathetic nerve activity was shown to inhibit hepatic triglyceride
(TG) excretion via modulation of liver stearyl-CoA desaturase (SCD)-1 activity in rodents. We evaluated
the impact of 7-h lactate clamping on VLDL-TG homeostasis in humans.
Methods: Eight normolipidemic, male subjects were subjected to a continuous infusion of L-lactate (target
concentration 3 mmol/L) or saline for 7 h in random order on two separate occasions. TG kinetics in very
low density lipoproteins (VLDL1 and 2) were measured after a bolus injection of [1,1,2,3,3]-2H5-glycerol.
Palmitic acid (16:0) and palmitoleic acid (16:1) in VLDL1 and VLDL2 were measured as a reﬂection of
liver SCD1 activity.
Results: Plasma TG levels changed by 0.16  0.09 mmol/L during lactate vs 0.15  0.08 mmol/L during
saline (P < 0.05). VLDL1 16:1/16:0 ratio increased to 1.2  0.7 during lactate versus a decrease during
saline by 1.5  0.6 (p ¼ 0.01). During lactate VLDL1-TG excretion was higher compared to saline (1604
[827e2870] versus 1285 [505e2155] mmol glycerol; p < 0.05), trending toward higher VLDL1-TG pool
sizes during lactate (28%; p ¼ 0.07 versus saline).
Conclusions: In normolipidemic men, 7-h L-lactate clamp increases, rather than decreases SCD1 activity
and hepatic TG secretion leading to elevated plasma TG levels. These conﬂicting data between human
and rodents on central regulation of hepatic TG excretion illustrate that experimental ﬁndings on the role
of the central nervous system in lipid metabolism should be interpreted with caution.
 2013 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Increased production of VLDL triglycerides (TGs) by the liver is a
hallmark of the metabolic syndrome and type 2 diabetes, leading to
increased plasma TG levels, accumulation of pro-atherogenic apoB-
containing lipoprotein particles and subsequent increased risk of
cardiovascular disease [1e4]. The production and secretion ofLDL, low density lipoprotein;
turase; TG, triglycerides; FFA,
de Y; BMI, body mass index;
er, Department of Vascular
e Netherlands. Tel.: þ31 20
amc.nl (E.S.G. Stroes).
er the Elsevier OA license.VLDL-TG by the liver is a complex process involving amongst others
endocrine and metabolic features [2,5]. Two distinct VLDL pop-
ulations can be discriminated. VLDL1 particles, the major fraction
secreted by the liver, are larger, less dense and contain more
triglycerides, whereas VLDL2 particles are smaller and more
cholesterol-enriched. The hepatic VLDL1 secretion rate from the
liver is more sensitive to metabolic changes such as the presence of
insulin resistance [6,7] and in familial combined hyperlipidemia
[8]. Free fatty acids (FFAs) derived from various sources, including
adipose tissue, de novo hepatic fatty acid synthesis but also FFA
from dietary sources [9], are required as a major substrate for he-
patic TG synthesis. A number of key molecules are essential in
hepatic VLDL processing. Microsomal triglyceride transfer protein
(MTP) enables ApoB containing lipoprotein assembly by promoting
fusion of precursor apoB particles with lipid droplets to form a
small VLDL particle [10]. The presence of monounsaturated fatty
B.M. Sondermeijer et al. / Atherosclerosis 228 (2013) 443e450444acids, derived from the action of stearoyl-CoA desaturase (SCD1)
enables further loading of TGs into the mature VLDL particles. SCD1
is a key enzyme catalyzing the formation of monounsaturated long-
chain fatty acids from saturated fatty acyl-CoAs [11e13]. The he-
patic desaturation index, which is the ratio of palmitoleic acid
(16:1) and palmitic acid (16:0), has been shown to reliably reﬂect
SCD1 activity [14,15].
A role for the central nervous system in controlling hepatic TG
production was proposed in multiple studies. TG production in
hyperinsulinemia was attenuated when infusing neuropeptide Y
(NPY) intra-cerebroventricularly (icv) in mice [16]. Inline, in fasting
rats an intact hypothalamic arcuate nucleus and hepatic sympa-
thetic innervation are required for the maintenance of hepatic TG
secretion [17]. More recently, Lam et al. elegantly showed that
hepatic vagal nerve activity was critically involved in the regulation
of hepatic VLDL-TG production in rodents [18]. Lactate adminis-
tration, either by systemic intravenous injection or by injection
directly into the brain, increased hypothalamic pyruvate levels
leading to metabolic alterations in glucose and lipid homeostasis.
Interestingly, icv administration of glucose, which is subsequently
metabolized to lactate in the hypothalamic region, led to a pro-
found reduction in hepatic VLDL-TG production in rodents. This
effect was abolished following disruption of the hepatic vagal
nerve. Mechanistically, CNS-stimulation of hepatic vagal nerve ac-
tivity was proposed to inhibit hepatic TG production via inhibition
of SCD1-activity [18,19]. These effects could also be reproduced in
rodents by peripheral lactate clamping, where doubling of plasma
lactate levels resulted in a w40% decrease of plasma TG concen-
tration. Based on these ﬁndings, a prominent role for CNS-
regulation in hypertriglyceridemia was put forward.
To evaluate whether these phenomena could be extrapolated to
the human setting, thereby offering potential new therapeutic
targets to treat hypertriglyceridemic states, we subjected normo-
lipidemic volunteers to a lactate clamp. Plasma lactatewas clamped
at 3 mmol/L during a period of 7 h. We measured [1,1,2,3,3]-2H5-
glycerol incorporation in TG in both VLDL1 and VLDL2 fractions to
assess TG production.
2. Methods
2.1. Subjects
Eight normolipidemic, male subjects were recruited through
advertisement. Subjects were healthy, had a median age of 24.5
years [23.3e33.5], an average BMI of 24.6  3.2 kg/m2 and did not
use any medication. Participants were excluded if they consumed
more than two units of alcohol per day, had a BMI >30.0 kg/m2,
used medication which could inﬂuence the glucose- or lipid
metabolism, had diabetes or hypertension. The institutional review
board of the Academic Medical Center of the University of
Amsterdam, the Netherlands, approved the study. All subjects
provided written informed consent. Clinical Trials.gov NCT-number
NTR2522 identiﬁes this study.
2.2. Experimental protocol
All study subjects were invited to the AMC on 2 separate days.
They received a lactate infusion on one day and a control isotonic
0.9% saline infusion on the other day. The saline infusion was per-
formed to exclude that the ingestion of a large amount of ﬂuid
would hamper the results. All subjects were admitted to the
research unit after an overnight fast. Three days before the study
subjects were asked to maintain a diet with at least 250 g of car-
bohydrates a day. One intravenous catheter was inserted into an
antecubital vein for infusion; a second intravenous catheter wasinserted retrogradely and put into a heated hand box to obtain
arterialized venous blood [20]. Saline was administered during a
30-min adaptation phase, thereafter saline or L-lactate 30% (IVAC
pump model 598) was given in random order during 2 separate
study days at least two weeks apart. L-Lactate 30% was infused to
reach a stable plasma lactate level of 3 mmol/L during 7 h with an
average infusion rate of 2.52 mg/kg/min [21]. When the plasma
lactate level had stabilized at 3 mmol/L, the participants received a
bolus of 100 mL (5 mg/mL) [1,1,2,3,3-2H5] glycerol (>99% enriched;
Cambridge Isotopes, Andover, MA, USA). The subjects did not
consume any food but were allowed to drink water during the
study day. Blood sampling started at 09:00 a.m. after the adaption
phase. Blood sampling was done before the injection of the tracer
and at 15, 30, 60, 90, 120, 150, 180, 240, 300, 360 and 390 min post-
tracer injection. The bed-side blood gas analyzer (Osmetech OPTI
CCA Analyzer, OPTI Medical Systems, Inc. Roswell, Georgia, USA)
was used to monitor pH levels instantaneously to keep the pH
under the level of 7.55. During the ﬁrst hour, every 10 min pH-
measurement was performed, thereafter every half an hour. With
the bedside lactate analyzer (YSI 2300 STAT Plus Glucose &
Lactate Analyzer, Xylem, New York, New York, United States) we
assessed the plasma lactate level every 10 min until 3 mmol/L was
reached. Lactate levels were further monitored throughout the
clamp every 30 min. All blood samples were collected on ice in
EDTA tubes, centrifuged within 10 min (T ¼ 4 C, 3000 rpm,
t ¼ 20 min) and stored at 80 C until analysis. During infusion the
subjects remained in resting position in a silent environment. Blood
glucose was measured using a bed-side calibrated glucose sensor
(YSI 2300 STAT S; YSI Yellow Springs, OH, USA). Triglycerides
(Randox, UK) and NEFA (DiaSys) were measured with a commer-
cially available colorimetric assay on the Cobas Mira system (Roche,
Switzerland). LDL cholesterol levels were analyzed with a com-
mercial assay from Wako (Neuss, Germany). Plasma apoB was
measured with a turbidimetric assay on the Cobas Mira system
(Roche, Switzerland). Plasma insulin was assessed using an ELISA
(Mercodia).
2.3. Preparation of Lþ-lactate infusion solution
30% Lþ-Lactic acid solution (w/w) and a 34.2% sodium-lactate
solution were manufactured under GMP conditions (Pharmacy
department, HAGA hospital, The Hague, The Netherlands). The ﬁnal
lactate infusion mixture was prepared by mixing 2.5 L of lactic acid
solution 30%, 14.3 L of sodium-lactate 34.2% and 2.05 L water. The
ﬁnal pH was 4.8. Subsequently, water for injection was added to a
ﬁnal volume of 20 L. After ﬁltration, the solution was ﬁlled in glass
bottles of 100 mL and sterilized (15 min, 121 C). Prior to admin-
istration, the lactate infusion mixture was diluted 1:9.5 with water
for injection.
2.4. Isolation of VLDL1 and VLDL2 fractions
VLDL1 and VLDL2 were isolated from 4 mL frozen plasma by
cumulative ultracentrifugation using a discontinuous salt gradient
using an SW41 rotor in Beckman L3-50 ultracentrifuge (Beckman
Inc., Palo Alto, CA 94034) [22,23]. The centrifuge tubes were coated
using polyvinylalcohol and isopropanolol (Merck, Darmstadt, Ger-
many). To increase the density to 1.21 g/mL Solid KBr (0.14 mg/mL)
was added. A discontinuous gradient was formed by addition of
2.5 mL of d ¼ 1.065 g/mL, d ¼ 1.020 g/mL and d ¼ 1.006 g/mL KBr
solutions respectively. The chylomicron fraction was collected in
the top 0.5 mL after centrifugation of 32 min at 36,000 rpm, 4 C.
VLDL1 and VLDL2 were isolated after respectively 3 h and 28 min
and 17 h at 4 C and 36,000 rpm. TG concentrations in all lipo-
protein fractions were determined by using a commercially
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Fig. 1. Schematic overview of the compartmental model of TG ﬂuxes. The model includes a single compartment for VDL1 and VLDL2 and an additional glycerol-phosphate pool
between glycerol and TG.
Table 1
Baseline characteristics of healthy subjects.
Healthy subjects (n ¼ 8)
Age (years) 24.5 [23.3e33.5]
Weight (kg) 82.8  16.6
Body mass index (kg/m2) 24.6  3.2
Alanine transaminase (U/L) 27.5 [22.8e37.5]
Plasma glucose (mmol/L) 5.1 [4.9e5.4]
TG (mmol/L) 0.8 [0.6e1.1]
Cholesterol (mmol/L) 4.9 [4.6e5.7]
HDLc (mmol/L) 1.5 [1.3e1.9]
LDLc (mmol/L) 3.1  0.5
ApoB (g/L) 0.9  0.2
Data are presented as mean  SD or median [IQR], TG: triglyceride; HDLc:
high density lipoprotein cholesterol; LDLc: low density lipoprotein choles-
terol; VLDL: very low density lipoprotein; apo: apolipoprotein.
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analyzer (ABX, Montpellier cedex, France). Fractions were frozen
at 80 C.
2.5. Measurement of 16:1/16:0 ratio as a reﬂection of SCD1 activity
Quantiﬁcation of plasma fatty acid esters was performed using a
HP7890AGas Chromatograph equippedwith an HP7683 Injector and
aHP5975CMass SelectiveDetector (Agilent Technologies, Santa Clara,
United States). Chromatography was performed using an HP-5MS
fused silica capillary column (30 m  0.25 mm inner diameter,
0.25 mm ﬁlm thickness, Agilent Technologies, Santa Clara, USA). The
GCeMS conditions were as follows: carrier gas, helium at a ﬂow-rate
of 1.1 mL/min; injector temperature, 250 C, split mode; oven tem-
perature 140 C, increased at 5 C/min to 300 C, and held for 10 min.
The mass spectrometer was operated under negative chemical ioni-
zation mode with methane as reactant gas. The ion source tempera-
ture and the quadrupole temperature were 150 C and 106 C
respectively. A SIM program was used for mass spectrometry quan-
tiﬁcation. Fatty acids were extracted from acidic plasma with ethyl-
acetate before its analysis by gas chromatography. The dried and
evaporated samples were derivatized with bis-(trimethylsilyl) tri-
ﬂuoroacetamide containing1% trimethylchlorosilane. The SCD1 index
was determined by calculating product:substrate ratios (16:1/16:0)
using the quantitated values for palmitoleic acid and palmitate.
2.6. Measurement of 2H5 glycerol enrichment in TG
in VLDL1 and VLDL2
Enrichment of [1,1,2,3,3,2H5] glycerol in TG present in VLDL1
and VLDL2 was measured as described in Ref. [24]. In short, 125 mL
VLDL1 or VLDL2was incubated with 125 mL lipase solution (1.25mg
lipase, SigmaeAldrich, St Louis, USA) and 0.21 mg colipase (Sigma)
10 mL albuman (Sanquin, Amsterdam, The Netherlands) for 16 h at
37 C. After incubation the glycerol was isolated using ion exchange
column chromatography as described in Ref. [24]. Glycerol con-
centration in VLDL1 and VLDL2 was analyzed using a commercial
assay from Diasys on a Cobas Mira autoanalyzer.
2.7. Compartmental modeling
TG ﬂuxes and pools were calculated according to the
compartmental model for plasma glycerol turnover described by
Adiels et al. [25] with minor modiﬁcations. A single plasma
compartment for VLDL1 and VLDL2 was used and an additional
glycerol-phosphate pool between glycerol and TG. This resulted in
the compartmental model shown in Fig. 1, in which pool sizes Q8,Q7, Q6, etc. refer to compartments, 8, 7, 6, etc and fractional
turnover rates k6,7, k4,6, k3,4, etc. refer to the fractional transfer
rate (FTR) of glycerol from compartment 7 to compartment 6, from
6 to 4, from 4 to 3, etc.
A number of assumptions were copied from Adiels et al. [25];
the average molar weight of TG is 885 and 1 mol TG equals 1 mol
glycerol. Total plasma volume is 4.5% of bodyweight, the average
plasma volume (V) was 3.7 L, which was used as a Bayesian value
(20%) for iterative modeling. Identical distribution volumes of
VLDL1, VLDL2 and glycerol were assumed. Plasma glycerol enrich-
ments were measured and thus FTRs k8,7 and k7,8 were estimated.
A ﬁve-compartment unit with a delay of 0.3 h VLDL was used to
model TG production (Fig. 1).
The concentration of [1,1,2,3,3]-2H5-glycerol at time point t (ct)
was calculated as the product of the atom percent enrichment at
this time point (APEt) and the mean glycerol concentration in a
particular compartment. So for VLDL1 at time point t:
Ct1 ¼ APEt1  C1
The pool sizes of [1,1,2,3,3]-2H5-glycerol in VLDL1, VLDL2, and
plasma i.e. q1, q2, and q7 were at each point in time calculated as
the products of their respective concentrations (Ct) at each time
point and plasma volume (V). So for VLDL1 at time point t:
qt1 ¼ V  Ct1
The ﬂux of glycerol was calculated as the product of FTR and
glycerol pool size. So for VLDL1 disposal at time point t:
FLUXt0;1 ¼ k0;1  Qt1
Average time dependent curves were constructed for
[1,1,2,3,3]-2H5-glycerol in VLDL1, VLDL2, and plasma of individuals
AB.M. Sondermeijer et al. / Atherosclerosis 228 (2013) 443e450446fromboth infusions. Themodelwasﬁtted to these curves using SAAM
II software (version 1.2.1, SAAM Institute University of Washington).
For this, plasma volume and k0,6 were introduced as Bayesian values
thatwere corrected for bodyweight of the subjects and the estimated
FTR as given by Adiels i.e. 3.7  0.75 L and 19  4.0 h1, respectively.
The FTRs were calculated as described by Adiels et al. formodeling of
plasma glycerol.
The obtained estimated values of the FTRs, and V, except FTRs of
interest i.e. k0,1, k0,2, and k2,1 were used as Bayesian values
(including an error of 20%) in ﬁtting the model to the curves of the
individual subjects. As a result, estimations of all FTRs were ob-
tained from all subjects in both infusions including the error in the
estimation.
2.8. Statistical analysis
Results are presented as mean  SD or median (interquartile
range) in Table 1. For the lactate infusion and saline day results areA 
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Fig. 2. A Plasma lactate levels during the 7-h lactate clamp and the 7-h saline clamp.
Data are presented as mean  SD. B Plasma glucose levels during the lactate as well as
saline clamp. Data are presented as mean  SD. C Plasma insulin levels during the
lactate as well as saline clamp. Data are presented as mean  SEM.presented as mean  SEM. We used SPSS software, version 16.0
(Chicago, IL, USA) and GraphPad Prism Software version 5.0 (CA,
USA). Differences were tested using a Student’s t-test (two-sided,
equal variances, paired) when the results were normally distrib-
uted, and ManneWhitney test otherwise. A probability value
P < 0.05 was considered to confer statistical signiﬁcance.
3. Results
3.1. Baseline characteristics
Baseline characteristics of the 8 participants are presented in
Table 1. The participants had median plasma TG level of 0.8
[0.6e1.1] mmol/L and a mean LDL cholesterol level of
3.1  0.5 mmol/L. Plasma apoB values were 0.9  0.2 g/L. TG0 100 200 300 400 500
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signiﬁcant higher VLDL1 16:1/16:0 ratio was observed (P < 0.01; lactate vs. saline).
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0.98  0.12 mmol/L and in the isolated VLDL2 was
0.67  0.1 mmol/L. During the lactate clamp a 5-fold increase
was achieved in plasma lactate levels during steady state
(3.06  0.05 mmol/L versus 0.65  0.02 mmol/L during saline
infusion) (Fig. 2), whereas plasma glucose concentrations during
lactate infusion remained unchanged at an average of
4.88  0.03 mmol/L versus 4.81  0.06 mmol/L (P ¼ 0.28) during
the saline infusion. No changes were observed during both in-
fusions periods for plasma insulin (Fig. 2C).
3.2. Triglyceride, VLDL-TG and 16:1/16:0 ratio
During the lactate clamp plasma TG levels increased from
0.95  0.13 mmol/L to 1.11  0.17 mmol/L (diffe-
rence ¼ 0.16  0.09 mmol/L, P < 0.05) (Fig. 3A). TG content in
isolated VLDL1 increased from 0.98  0.06 mmol/L to
1.12  0.05 mmol/L (P < 0.05), whereas TG content in isolated
VLDL2 was unaffected (0.67  0.08 to 0.79  0.10 mmol/L)
(P ¼ 0.11). During saline infusion plasma TG levels decreased from0.90  0.18 to 0.75  0.12 mmol/L (0.15  0.06 mmol/L; P < 0.05;
Fig. 3A) without signiﬁcant changes in TG content in VLDL1
(0.72  0.1 to 0.81  0.1 mmol/L; P ¼ 0.12) and VLDL2 (0.65  0.1 to
0.64  0.1 mmol/L; P ¼ 0.9). No changes in plasma FFA were
observed (Fig. 3B). The 16:1/16:0 ratio in isolated VLDL1 fraction
during lactate infusion increased from baseline to 1.2  0.74
(P < 0.01 vs. saline infusion; Fig. 3B). Saline infusion resulted in a
decrease of the 16:1/16:0 ratio in VLDL1 from baseline to end of
saline infusion (change1.5 0.55; P< 0.05 vs baseline). 16:1/16:0
ratio in VLDL2 did not change during either infusion.
3.3. Hepatic VLDL-TG ﬂuxes
The glycerol enrichment curves in plasma, VLDL1 and VLDL2
during saline and lactate infusion are shown in Figs. 4 and 5. The
total turnover of labeled glycerol in the administrated pool was
comparable (Fig. 4C), as was the fraction of labeled glycerol that
was directly converted, probably to glycerol-phosphate i.e. 98.5%
(data not shown). On average less than 1% of the glycerol-
phosphate was used for plasma TG synthesis.
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phosphate ﬂux (k4,6) into the hepatic TG fraction as compared to
saline infusion leading to an increased VLDL-TG assembly (k3,4)
and an increased ﬂux into the hepatic TG pool (k5,4) (Fig. 1). In line,
there was a trend toward a higher glycerol secretion rate into
VLDL1-TG (FLUX1,3) during lactate infusion compared to saline
infusion (1604 mmol (827e2870) vs. 1285 mmol (505e2155),
respectively; P ¼ 0.07 Figs. 4D and 5A). The incorporation of TG
directly in VLDL2 (FLUX2,3) was 18% higher during lactate infusion
(median saline: 311 mmol (117e475) versus lactate: 465 mmol (42e
1019)), but this difference was not statistically signiﬁcant (Fig. 5A).
Correspondingly, both the VLDL1-TG as well as the VLDL2-TG pool
sizes were increased by 28% and 18% during lactate (Fig. 5A).
During lactate infusion we observed a signiﬁcant decreased
transfer of labeled glycerol from VLDL1 to VLDL2 (FLUX2,1), leading
to a higher VLDL1-TG pool (saline: 804 mmol (412e1634) vs lactate
504 mmol (245e533); P < 0.01; Fig. 5A). Similarly, the clearance of
VLDL2-TG (FLUX0,2) during lactate infusion decreased by 22% (sa-
line 1158 mmol glycerol (670e2006) versus lactate: 972 mmol
glycerol (546e1430)), although the difference in VLDL2-TG levels
did not reach statistical signiﬁcance.
4. Discussion
In the present study we show that a 7-h L-lactate clamp in hu-
man increases, rather than decreases hepatic VLDL-TG secretion,
leading to higher TG concentrations in the VLDL1 fraction. SCD1
activity in VLDL1 was also higher during lactate infusion. These
opposite ﬁndings in humans compared to those obtained in rodent
models emphasize that data on central regulation of hepatic TG
excretion in experimental models should be interpreted with great
caution in the human setting.
Lactate has been suggested to interfere with lipolysis and
glucose utilization, since lactate is metabolized into pyruvate by the
enzyme lactate dehydrogenase [21]. In previous studies, however,
systemic lactate infusion in humans did not signiﬁcantly affect
glucose and FFAmetabolism [21,26]. In contrast, Lam et al. elegantly
demonstrated that intra-cerebroventricular infusion of either
glucose or lactate resulted in an increased vagal signaling to the
liver, in turn leading to decreased hepatic TG excretion in rodents
[18]. Inhibition of lactate generation by central administration of
oxamate, an inhibitor of the enzyme lactate dehydrogenase,
attenuated the observed effects, suggesting that the hypothalamus
is instrumental in the observed effects [19]. This effect could be
reproduced by systemic lactate clamping to values twice the
physiological lactate levels [18]. In support, lactate crosses the
bloodebrain barrier [27] and the recently proposed astrocytee
neuron lactate shuttle hypothesis suggests that lactate is even
actively transferred to neurons in the brain, particularly in the
hypothalamic region where ﬁbers innervating visceral organs
originate [28]. Mechanistically, SCD1 activity in the liver, an
important mediator involved in regulation of hepatic VLDL-TG
secretion, was found to be responsible for the observed effects of
icv lactate on hepatic VLDL-TG secretion.
In view of the therapeutic potential of such CNS-pathway
regulating hepatic TG-excretion, we tested the validity of this
concept in humans. To minimize the chance of a false negative
ﬁnding, we generated a 5-fold increase in plasma lactate levels
during a period of 7 h. In spite of the marked increase and pro-
longed duration of the lactate clamp, we observed an increase,
rather than a decrease in hepatic VLDL-TG excretion. The increase
in hepatic VLDL1-TG secretion was corroborated by an increased
SCD1 activity, as shown by a higher plasma VLDL1 16:1/16:0 ratio.
This increase of TG ﬂux through the VLDL pathway, however, did
not result in differences in VLDL subfraction clearance. Thus ourdata suggest that excess lactate is directly converted into pyruvate
and used as substrate into the TCA cycle leading to increased citrate
synthesis which after transport to the cytoplasm induces increased
FFA and hence TG production.5. Limitations
Several aspects need closer considerationwhen interpreting the
results of this study. A major limitation of the present study is that
our study population was relatively small due to the costly nature
and laborious lab procedures. Moreover, we used healthy controls
and cannot establish whether results apply to individuals with
abnormal plasma lipid levels. Despite this limitation, we observed
signiﬁcant and coherent data showing an increase rather than a
decrease in hepatic VLDL1-TG excretion following a lactate clamp.
Second, we studied healthy volunteers rather than patients char-
acterized by perturbed lipid metabolism. Thus, we cannot exclude
that in patients with increased hepatic VLDL excretion, such as e.g.
familial combined hyperlipidemia, an effect could have been
observed. Finally, our study protocol in humans does not allow us to
demonstrate that peripheral lactate infusion reached steady state
increase of lactate at the level of the hypothalamus, nor could we
validate that lactate clamping resulted in direct changes in hepatic
vagal nerve activity. However, in our study we did generate a 5-fold
increase in plasma lactate levels during a period of 7 h, which can
be expected to increase lactate concentration at the level of the
hypothalamus.
In summary, plasma lactate clamping in healthy volunteers
during a period of 7 h results in increased VLDL-TG excretion and
increased VLDL1 SCD1 activity. Our data indicate that experimental
ﬁndings on central regulation of hepatic TG-excretion in rodents
cannot be extrapolated to the human setting.Disclosure statement
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